Karyopharm to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023

Rhea-AI Summary

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) announced it will release its fourth quarter and full year 2022 financial results on February 15, 2023, during a conference call at 8:00 a.m. ET. The call will cover financial results and company updates. Karyopharm is known for developing novel cancer therapies, including its lead compound, XPOVIO® (selinexor), which is approved in the U.S. for multiple oncology indications. The company is focused on addressing high unmet needs in cancer treatment.

Positive

• Karyopharm's XPOVIO® is a first-in-class oral XPO1 inhibitor approved in the U.S. for multiple oncology indications.
• The company has regulatory approvals for XPOVIO® in Europe, the U.K., and China.

Negative

• None.

-- Conference Call Scheduled for Wednesday, February 15, 2023, at 8:00 a.m. ET --

NEWTON, Mass., Feb. 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Wednesday, February 15, 2023, to discuss the financial results and other company updates.

To access the conference call, please dial (888) 349-0102 (local) or (412) 902-4299 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic neoplasms and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-15-2023-301739512.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When will Karyopharm report its financial results for 2022?

Karyopharm will report its fourth quarter and full year 2022 financial results on February 15, 2023.

What time is the Karyopharm conference call scheduled for?

The Karyopharm conference call is scheduled for 8:00 a.m. ET on February 15, 2023.

How can I access Karyopharm's conference call?

You can access the conference call by dialing (888) 349-0102 or (412) 902-4299 and joining the Karyopharm call.

What is Karyopharm Therapeutics known for?

Karyopharm is known for pioneering novel cancer therapies, particularly its lead compound XPOVIO®.